Triad Life Sciences, Inc. developed a ground-breaking, FDA-cleared technology platform engineered to address unmet clinical needs in complex surgical wounds, chronic stalled wounds, and burns. Following our pre-IPO investment, the company received a takeover offer at a significant premium to our entry price.